Molecular Insight reports positive trial results

Molecular Insight Pharmaceuticals said that a phase IIB clinical trial of its Zemiva radiopharmaceutical has yielded positive results.

Prospective analysis of the clinical trial data suggests that the addition of quantitative SPECT imaging with Zemiva to clinical information obtained in an emergency department setting has significant clinical value in rapidly identifying chest pain patients at high risk for acute coronary syndrome.

The Cambridge, MA-based firm presented the analysis in a poster at this week's 2008 scientific sessions of the American Heart Association (AHA) in New Orleans.

Related Reading

Molecular Insight installs interim CEO, September 26, 2008

Molecular Insight touts Trofex studies, June 18, 2008

Molecular Insight starts Trofex trial, June 12, 2008

Molecular Insight's revenue decreases in Q1, May 14, 2008

Molecular Insight launches new Azedra trials, May 1, 2008

Copyright © 2008 AuntMinnie.com

Page 1 of 435
Next Page